세계의 겸상 적혈구증 치료 시장 점유율, 규모, 동향, 산업 분석 리포트 : 치료법별, 최종사용자별, 지역별, 부문 예측(2022-2030년)

The global sickle cell disease treatment market size is expected to reach USD 6.94 billion by 2030, according to a new study by Polaris Market Research. The report "Sickle Cell Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant); By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The significant number of unmet medical needs, a healthy pipeline, and a growing patient pool are all expected to boost market growth. As a result of the lack of a complete cure and the risks associated with bone marrow transplantation, there has been an increase in demand for cost-effective drugs and gene therapy for sickle cell disease (SCD) in recent years.

Gene therapy has appeared as the ultimate solution for several critical ailments. In the case of genetic disorders, gene therapy represents a revolution that addresses the disease's underlying cause. Companies are moving their R&D attention to genetic therapy to fix the genetic mutation in SCD.

Moreover, in May 2020, CRISPER Therapeutics and Vertex Pharmaceuticals are also undertaking clinical studies for CTX001, a CRISPR-Cas9 gene-edited treatment. They confirmed that the FDA had granted CTX001, an interventional, patient-derived, gene-edited stem cell-derived hematopoietic therapy, Regenerative Medicine Advanced Therapy (RMAT) distinction for the treatment of serious sickle cell disorder, and transfusion-dependent beta-thalassemia (TDT).

Positive clinical tests on CTX001 indicate that the pipeline candidate has the potential to become a blockbuster medicine when it is released. This is projected to drive significant expansion in the SCD therapy industry. Furthermore, the government is funding research and development (R&D) operations designed to motivate researchers and pharmaceutical businesses to create novel medicines.

Sickle Cell Disease Treatment Market Report Highlights

Bone Marrow Transplant (BMT) segment is anticipated to grow at a significant CAGR over the forecast period. Only bone marrow transplantation (BMT) can cure SCD. As a result, the preference for BMT is growing throughout North America and Europe. However, the procedure's high cost and difficulties in locating a matched donor restrict the segment's growth.

Pharmacotherapy segment accounted for a significant revenue share. The government's significant support for pharmaceutical businesses can be ascribed to the segment's rapid expansion. Because there are currently few therapy choices on the market, the government encourages research through financing and classifications like orphan pharmaceuticals, fast track, issues that will affect, and others.

Asia Pacific is expected to grow at a lucrative CAGR over the projected period. Because of a rising patient population and increasing disposable income levels in this region. Furthermore, the expansion of the healthcare system and increasing government efforts would accelerate the market's growth in this region.

The global players with a global presence include AstraZeneca, Acceleron Pharma, Inc., Arena Pharmaceuticals, Emmaus Life Sciences, Blood Therapeutics, Novartis, Pfizer Incorporation, and Sangamo Therapeutics.

Polaris Market Research has segmented the sickle cell disease treatment market report based on treatment, end-use, and region:

Sickle Cell Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2018 - 2030)

Blood Transfusion

Pharmacotherapy

Hydroxyurea

Branded Drugs

Endari

Adakveo

Oxbryta

Zynteglo

CTX001

Mitapivat

FT-4202

Bone Marrow Transplant

Sickle Cell Disease Treatment, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Specialty Clinics

Others

Sickle Cell Disease Treatment, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Sickle Cell Disease Treatment Market Insights

• 4.1. Sickle Cell Disease Treatment Market - Industry Snapshot
• 4.2. Sickle Cell Disease Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. High unmet needs
    • 4.2.1.2. Increasing prevalence of hemoglobinopathies in under-developed countries
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Lack of healthcare infrastructure
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Sickle Cell Disease Treatment Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Sickle Cell Disease Treatment Market, by Treatment

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Sickle Cell Disease Treatment, by Treatment, 2018 - 2030 (USD Billion)
• 5.3. Blood Transfusion
  • 5.3.1. Global Sickle Cell Disease Treatment Market, by Blood Transfusion, by Region, 2018 - 2030 (USD Billion)
• 5.4. Pharmacotherapy
  • 5.4.1. Global Sickle Cell Disease Treatment Market, by Pharmacotherapy, by Region, 2018 - 2030 (USD Billion)
  • 5.4.2. Hydroxyurea
    • 5.4.2.1. Global Sickle Cell Disease Treatment Market, by Hydroxyurea, by Region, 2018 - 2030 (USD Billion)
  • 5.4.3. Branded Drugs
    • 5.4.3.1. Global Sickle Cell Disease Treatment Market, by Branded Drugs, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.2. Endari
    • 5.4.3.2.1. Global Sickle Cell Disease Treatment Market, by Endari, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.3. Adakveo
    • 5.4.3.3.1. Global Sickle Cell Disease Treatment Market, by Adakveo, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.4. Oxbryta
    • 5.4.3.4.1. Global Sickle Cell Disease Treatment Market, by Oxbryta, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.5. Zynteglo
    • 5.4.3.5.1. Global Sickle Cell Disease Treatment Market, by Zynteglo, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.6. CTX001
    • 5.4.3.6.1. Global Sickle Cell Disease Treatment Market, by CTX001, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.7. Mitapivat
    • 5.4.3.7.1. Global Sickle Cell Disease Treatment Market, by Mitapivat, by Region, 2018 - 2030 (USD Billion)
    • 5.4.3.8. FT-4202
    • 5.4.3.8.1. Global Sickle Cell Disease Treatment Market, by FT-4202, by Region, 2018 - 2030 (USD Billion)
• 5.5. Bone Marrow Transplant
  • 5.5.1. Global Sickle Cell Disease Treatment Market, by Bone Marrow Transplant, by Region, 2018 - 2030 (USD Billion)

6. Global Sickle Cell Disease Treatment Market, by End-Use

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
• 6.3. Hospitals
  • 6.3.1. Global Sickle Cell Disease Treatment Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
• 6.4. Specialty Clinics
  • 6.4.1. Global Sickle Cell Disease Treatment Market, by Specialty Clinics, by Region, 2018 - 2030 (USD Billion)
• 6.5. Others
  • 6.5.1. Global Sickle Cell Disease Treatment Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Sickle Cell Disease Treatment Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Sickle Cell Disease Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• 7.3. Sickle Cell Disease Treatment Market - North America
  • 7.3.1. North America: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.3.2. North America: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.3.3. Sickle Cell Disease Treatment Market - U.S.
    • 7.3.3.1. U.S.: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.3.3.2. U.S.: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.3.4. Sickle Cell Disease Treatment Market - Canada
    • 7.3.4.1. Canada: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.3.4.2. Canada: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
• 7.4. Sickle Cell Disease Treatment Market - Europe
  • 7.4.1. Europe: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.4.2. Europe: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.3. Sickle Cell Disease Treatment Market - UK
    • 7.4.3.1. UK: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.3.2. UK: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.4. Sickle Cell Disease Treatment Market - France
    • 7.4.4.1. France: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.4.2. France: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.5. Sickle Cell Disease Treatment Market - Germany
    • 7.4.5.1. Germany: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.5.2. Germany: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.6. Sickle Cell Disease Treatment Market - Italy
    • 7.4.6.1. Italy: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.6.2. Italy: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.7. Sickle Cell Disease Treatment Market - Spain
    • 7.4.7.1. Spain: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.7.2. Spain: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.8. Sickle Cell Disease Treatment Market - Netherlands
    • 7.4.8.1. Netherlands: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.8.2. Netherlands: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.4.9. Sickle Cell Disease Treatment Market - Russia
    • 7.4.9.1. Russia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.9.2. Russia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
• 7.5. Sickle Cell Disease Treatment Market - Asia Pacific
  • 7.5.1. Asia Pacific: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.5.2. Asia Pacific: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.3. Sickle Cell Disease Treatment Market - China
    • 7.5.3.1. China: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.3.2. China: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.4. Sickle Cell Disease Treatment Market - India
    • 7.5.4.1. India: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.4.2. India: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.5. Sickle Cell Disease Treatment Market - Malaysia
    • 7.5.5.1. Malaysia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.5.2. Malaysia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.6. Sickle Cell Disease Treatment Market - Japan
    • 7.5.6.1. Japan: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.6.2. Japan: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.7. Sickle Cell Disease Treatment Market - Indonesia
    • 7.5.7.1. Indonesia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.7.2. Indonesia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.5.8. Sickle Cell Disease Treatment Market - South Korea
    • 7.5.8.1. South Korea: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.8.2. South Korea: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
• 7.6. Sickle Cell Disease Treatment Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.6.2. Middle East & Africa: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.6.3. Sickle Cell Disease Treatment Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.6.4. Sickle Cell Disease Treatment Market - UAE
    • 7.6.4.1. UAE: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.4.2. UAE: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.6.5. Sickle Cell Disease Treatment Market - Israel
    • 7.6.5.1. Israel: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.5.2. Israel: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.6.6. Sickle Cell Disease Treatment Market - South Africa
    • 7.6.6.1. South Africa: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.6.2. South Africa: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
• 7.7. Sickle Cell Disease Treatment Market - Latin America
  • 7.7.1. Latin America: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.7.2. Latin America: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.7.3. Sickle Cell Disease Treatment Market - Mexico
    • 7.7.3.1. Mexico: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.3.2. Mexico: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.7.4. Sickle Cell Disease Treatment Market - Brazil
    • 7.7.4.1. Brazil: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.4.2. Brazil: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 7.7.5. Sickle Cell Disease Treatment Market - Argentina
    • 7.7.5.1. Argentina: Sickle Cell Disease Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.5.2. Argentina: Sickle Cell Disease Treatment Market, by Treatment, 2018 - 2030 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. AstraZeneca Plc.
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Acceleron Pharma, Inc.
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Arena Pharmaceuticals, Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Alnylam Pharmaceuticals, Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Baxter International Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Bristol-Myers Squibb Company
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. Bluebird bio, Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Emmaus Life Sciences, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Eli Lilly and Company
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Global Blood Therapeutics Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Novartis AG
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development
• 9.12. Pfizer Inc.
  • 9.12.1. Company Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Development
• 9.13. Sangamo Therapeutics, Inc.
  • 9.13.1. Company Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Development